A-770041Selective Lck inhibitor CAS# 869748-10-7 |
2D Structure
- KX2-391 dihydrochloride
Catalog No.:BCC1686
CAS No.:1038395-65-1
- Dasatinib (BMS-354825)
Catalog No.:BCC1281
CAS No.:302962-49-8
- Saracatinib (AZD0530)
Catalog No.:BCC1166
CAS No.:379231-04-6
- Bosutinib (SKI-606)
Catalog No.:BCC1167
CAS No.:380843-75-4
- Dasatinib hydrochloride
Catalog No.:BCC1517
CAS No.:854001-07-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 869748-10-7 | SDF | Download SDF |
PubChem ID | 9549184 | Appearance | Powder |
Formula | C34H39N9O3 | M.Wt | 621.75 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 100 mg/mL (160.84 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | N-[4-[1-[4-(4-acetylpiperazin-1-yl)cyclohexyl]-4-aminopyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methylindole-2-carboxamide | ||
SMILES | CC(=O)N1CCN(CC1)C2CCC(CC2)N3C4=C(C(=N3)C5=CC(=C(C=C5)NC(=O)C6=CC7=CC=CC=C7N6C)OC)C(=NC=N4)N | ||
Standard InChIKey | ZMNWFTYYYCSSTF-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C34H39N9O3/c1-21(44)41-14-16-42(17-15-41)24-9-11-25(12-10-24)43-33-30(32(35)36-20-37-33)31(39-43)23-8-13-26(29(19-23)46-3)38-34(45)28-18-22-6-4-5-7-27(22)40(28)2/h4-8,13,18-20,24-25H,9-12,14-17H2,1-3H3,(H,38,45)(H2,35,36,37) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | A-770041 is selective and orally active Src-family Lck inhibitor; A-770041 is a 147 nM inhibitor of Lck (1 mM ATP) and is 300-fold selective against Fyn, the other Src family kinase involved in T-cell signaling.
IC50 value: 147 nM
Target: Lck References: |
A-770041 Dilution Calculator
A-770041 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.6084 mL | 8.0418 mL | 16.0836 mL | 32.1673 mL | 40.2091 mL |
5 mM | 0.3217 mL | 1.6084 mL | 3.2167 mL | 6.4335 mL | 8.0418 mL |
10 mM | 0.1608 mL | 0.8042 mL | 1.6084 mL | 3.2167 mL | 4.0209 mL |
50 mM | 0.0322 mL | 0.1608 mL | 0.3217 mL | 0.6433 mL | 0.8042 mL |
100 mM | 0.0161 mL | 0.0804 mL | 0.1608 mL | 0.3217 mL | 0.4021 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
The src-family of tyrosine kinases comprises eight highly homologous proteins that are primarily expressed in hematopoietic tissues, two of which, lck and fyn, are expresse in T cells. Lck plays a critical function during the initial steps of T-cell-receptor signaling resulting in a cascade of downstream signaling pathways. A-770041 is an orally bioavailable pyrazolo[3,4-d]pyrimidine exhibiting selectivity for Lck compared with previously reported compounds.
In vitro: A-770041 is a 147 nM inhibitor of Lck (1 mM ATP) and is 300-fold selective against Fyn when compoared with the other involved Src family kinase. It was found that concanavalin A-stimulated IL-2 production in whole blood could be inhibited by A-770041 with an EC50 of approximately 80 nM [1].
In vivo: A-770041 is orally bioavailable (F = 34.1 ± 7.2% at 10 mg/kg) and has a t1/2 of 4.1 ± 0.1 h. Concanavalin A-induced IL-2 production in vivo is inhibited by oral administration of A-770041 (in vivo EC50 = 78 ± 28 nM). Doses of A-770041 at or above 10 mg/kg/day prevent rejection of hearts transplanted heterotopically in rats from Brown Norway donors to Lewis recipients across a major histocompatibility barrier for least 65 days. Moreover, grafts from animals treated with 20 mg/kg/day A-770041 or 10 mg/day Cyclosporin A had minimal microvascular changes or multifocal mononuclear infiltrates. In contract, mineralization in myocytes from the grafts from A-770041-treated animals was less than animals treated with Cyclosporin A [1].
Clinical trial: A-770041 is currently in the preclinical developlent stage and no clinical data are available.
Reference:
[1] Stachlewitz RF, Hart MA, Bettencourt B, Kebede T, Schwartz A, Ratnofsky SE, Calderwood DJ, Waegell WO, Hirst GC. A-770041, a novel and selective small-molecule inhibitor of Lck, prevents heart allograft rejection. J Pharmacol Exp Ther. 2005;315(1):36-41.
- Obestatin (rat)
Catalog No.:BCC5912
CAS No.:869705-22-6
- Fmoc-Tyr(tBu)-ol
Catalog No.:BCC2572
CAS No.:86967-51-3
- Tecovirimat
Catalog No.:BCC5518
CAS No.:869572-92-9
- JNJ 10191584 maleate
Catalog No.:BCC7362
CAS No.:869497-75-6
- Praeroside II
Catalog No.:BCN7001
CAS No.:86940-46-7
- 14-Deoxy-17-hydroxyandrographolide
Catalog No.:BCN4560
CAS No.:869384-82-7
- MLN8054
Catalog No.:BCC2170
CAS No.:869363-13-3
- AZD8330
Catalog No.:BCC3733
CAS No.:869357-68-6
- Neurokinin B (human, porcine)
Catalog No.:BCC7119
CAS No.:86933-75-7
- Neurokinin A (porcine)
Catalog No.:BCC6955
CAS No.:86933-74-6
- PF-573228
Catalog No.:BCC4496
CAS No.:869288-64-2
- SB 203580 hydrochloride
Catalog No.:BCC4293
CAS No.:869185-85-3
- threo-Guaiacylglycerol beta-coniferyl ether
Catalog No.:BCN1323
CAS No.:869799-76-8
- A 841720
Catalog No.:BCC7550
CAS No.:869802-58-4
- Andropanolide
Catalog No.:BCN4559
CAS No.:869807-57-8
- Formoxanthone A
Catalog No.:BCN6451
CAS No.:869880-32-0
- Radezolid
Catalog No.:BCC1882
CAS No.:869884-78-6
- VRT752271
Catalog No.:BCC4122
CAS No.:869886-67-9
- Alpinumisoflavone acetate
Catalog No.:BCN6813
CAS No.:86989-18-6
- MK-2048
Catalog No.:BCC2136
CAS No.:869901-69-9
- TLQP 21
Catalog No.:BCC2405
CAS No.:869988-94-3
- Thiolutin
Catalog No.:BCC2471
CAS No.:87-11-6
- Salicylanilide
Catalog No.:BCC4712
CAS No.:87-17-2
- Ac-DL-Trp-OH
Catalog No.:BCC3119
CAS No.:87-32-1
A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.[Pubmed:25236161]
BMC Cancer. 2014 Sep 19;14:681.
BACKGROUND: Reversing multidrug resistance (MDR) has been an important goal for clinical and investigational oncologists. In the last few decades, significant effort has been made to search for inhibitors to reverse MDR by targeting ATP-binding cassette (ABC) transporters (Pgp, MRP) directly, but these efforts have achieved little clinical success. Protein kinases play important roles in many aspects of tumor cell growth and survival. Combinations of kinase inhibitors and chemotherapeutics have been observed to overcome cancer drug resistance in certain circumstances. METHODS: We screened a kinase specific inhibitor compound library in human osteosarcoma MDR cell lines to identify inhibitors that were capable of reversing chemoresistance to doxorubicin and paclitaxel. RESULTS: We identified 18 small molecules that significantly increase chemotherapy drug-induced cell death in human osteosarcoma MDR cell lines U-2OSMR and KHOSR2. We identified A-770041 as one of the most effective MDR reversing agents when combined with doxorubicin or paclitaxel. A-770041 is a potent Src family kinase (Lck and Src) inhibitor. Western blot analysis revealed A-770041 inhibits both Src and Lck activation and expression. Inhibition of Src expression in U-2OSMR and KHOSR2 cell lines using lentiviral shRNA also resulted in increased doxorubicin and paclitaxel drug sensitivity. A-770041 increases the intracellular drug accumulation as demonstrated by calcein AM assay. CONCLUSIONS: These results indicate that small molecule inhibitor A-770041 may function to reverse ABCB1/Pgp-mediated chemotherapy drug resistance. Combination of Src family kinase inhibitor with regular chemotherapy drug could be clinically effective in MDR osteosarcoma.
A-770041, a novel and selective small-molecule inhibitor of Lck, prevents heart allograft rejection.[Pubmed:16014572]
J Pharmacol Exp Ther. 2005 Oct;315(1):36-41.
Lck, one of eight members of the Src family of tyrosine kinases, is activated after T cell stimulation and is required for T-cell proliferation and interleukin (IL)-2 production. Inhibition of Lck has been a target to prevent lymphocyte activation and acute rejection. Here, we report the pharmacologic characterization of 1-methyl-1H-indole-2-carboxylic acid (4-{1-[4-(4-acetyl-piperazin-l-yl)-cyclohexyl]-4-amino-1H-pyrazolo[3,4-d]pyrimidi n-3-yl}-2-methoxy-phenyl)-amide (A-770041), an orally bioavailable pyrazolo[3,4-d]pyrimidine with increased selectivity for Lck compared with previously reported compounds. A-770041 is a 147 nM inhibitor of Lck (1 mM ATP) and is 300-fold selective against Fyn, the other Src family kinase involved in T-cell signaling. Concanavalin A-stimulated IL-2 production in whole blood is inhibited by A-770041 with an EC50 of approximately 80 nM. A-770041 is orally bioavailable (F = 34.1 +/- 7.2% at 10 mg/kg) and has a t(1/2) of 4.1 +/- 0.1 h. Concanavalin A-induced IL-2 production in vivo is inhibited by oral administration of A-770041 (in vivo EC50 = 78 +/- 28 nM). Doses of A-770041 at or above 10 mg/kg/day prevent rejection of hearts transplanted heterotopically in rats from Brown Norway donors to Lewis recipients across a major histocompatibility barrier for least 65 days. Grafts from animals treated with 20 mg/kg/day A-770041 or 10 mg/day Cyclosporin A had minimal microvascular changes or multifocal mononuclear infiltrates. However, mineralization in myocytes from the grafts from A-770041-treated animals was less than animals treated with Cyclosporin A. Lck inhibition is an attractive target to prevent acute rejection.
Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection.[Pubmed:16216497]
Bioorg Med Chem Lett. 2006 Jan 1;16(1):118-22.
We describe the identification, SAR, and pharmacology of the src-family selective lck inhibitor A-770041 that prolongs the survival of major histocompatibility mismatched allografts in models of solid organ transplant rejection for greater than 65 days.